Stockscreener 앱 받기
836.09
0.01%
0.10
시장 영업 전:
832.01
-4.08
-0.49%
Argen X Se Adr 주식(ARGX)의 최신 뉴스
Stifel raises argenx stock price target on myositis study outlook By Investing.com - Investing.com Australia
Stifel raises argenx stock price target on myositis study outlook - Investing.com
ARGX.BR Stock Price, Quote & Chart | ARGENX SE (EBR:ARGX) - ChartMill
Barlow’s Research Roundup: RBC analyst provides praise and top picks in regulated utilities sector - The Globe and Mail
argenx to Present at Upcoming Investor Conferences - GlobeNewswire Inc.
ARGX Stock Price, Quote & Chart | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
Argenx SE stock (NL0010832176): autoimmune drug specialist in focus after recent price strength - AD HOC NEWS
Evercore ISI Raises its Price Target on argenx (ARGX) - Yahoo Finance
ARGX News | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
Jefferies updates franchise picks list, adding AMZN, APP, MCD and more - MSN
argenx SE’s SWOT analysis: stock gains momentum on Vyvgart growth By Investing.com - Investing.com Nigeria
argenx SE’s SWOT analysis: stock gains momentum on Vyvgart growth - Investing.com
argenx SE (ARGX) Stock Price, Trades & News - GuruFocus
Argenx SE stock (NL0010832176): FMR LLC boosts stake amid price gains - AD HOC NEWS
Earnings call transcript: Argenx Q1 2026 beats EPS expectations, stock dips - Investing.com
Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease - Sahm
argenx stock gains after FDA expands MG treatment approval By Investing.com - Investing.com South Africa
argenx stock gains after FDA expands MG treatment approval - Investing.com
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG - ChartMill
RBC Capital maintains argenx stock price target at $890 on uptake potential - Investing.com Australia
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 By Investing.com - Investing.com Australia
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 - Investing.com
Argenx beats profit forecasts despite revenue miss - Investing.com
Argenx beats profit forecasts despite revenue miss By Investing.com - Investing.com Canada
argenx posts 63% revenue growth on strong Vyvgart sales By Investing.com - Investing.com South Africa
argenx appoints Karen Massey as CEO, founder moves to chair - Investing.com
argenx appoints Karen Massey as CEO, founder moves to chair By Investing.com - Investing.com India
argenx to Present at BofA Securities 2026 Health Care Conference - ChartMill
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer - ChartMill
Argenx SE Q1 2026 earnings preview - MSN
Here’s Why Argenx SE (ARGX) Slipped in Q1 - Yahoo Finance
ARGX.BR Technical Analysis | Trend, Signals & Chart Patterns | ARGENX SE (EBR:ARGX) - ChartMill
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 - ChartMill
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Regeneron (REGN) - The Globe and Mail
argenx SE Stock Baskets | MEX:ARGXN - GuruFocus
argenx SE Stock Operating Data - GuruFocus
argenx SE (MEX:ARGXN) Stock News, Headlines & Updates - GuruFocus
US-Listed European ADRs Slipped As Drugmakers Weighed On The Tape - Finimize
Argenx SE stock (NL0010832176): Is its rare disease focus strong enough to unlock sustained U.S. gro - AD HOC NEWS
2.30%
3.94%
자본화:
|
볼륨(24시간):